Are There Blood-Based Biomarkers for ADHD?

PostedOctober 7, 2025

UpdatedOctober 10, 2025

ByMy Patient Advice

Author: Victoria Rowe, MSc | Reviewed by: Dr. Rebecca Fernandez, MBBS

The search for objective, biological clues to aid in diagnosing ADHD has turned scientists’ attention to blood biomarkers. These measurable substances in the bloodstream may reflect underlying changes in brain chemistry, offering a non-invasive way to identify or monitor ADHD. While still in the research phase, certain blood biomarkers linked to dopamine, norepinephrine, and even inflammation is showing early promise.

Dopamine and Norepinephrine in the Blood

ADHD is closely tied to imbalances in dopamine and norepinephrine, neurotransmitters essential for attention, motivation, and self-regulation. Some studies have attempted to measure metabolites of these chemicals, such as homovanillic acid (HVA) for dopamine or 3-methoxy-4-hydroxyphenylglycol (MHPG) for norepinephrine, in blood or plasma. However, levels in the blood do not always directly reflect brain activity, so these remain indirect markers rather than definitive diagnostics.

Inflammation Markers and Emerging Evidence

Beyond neurotransmitters, researchers have begun exploring inflammatory markers as potential blood biomarkers for ADHD. Elevated levels of cytokines such as IL-6 and TNF-alpha have been found in some children with ADHD, suggesting that immune system activity might play a role in the disorder. This opens new avenues of investigation linking brain function with systemic health.

Conclusion

While no blood-based biomarker is currently validated for routine ADHD diagnosis, research is steadily progressing. These findings hold the potential for more accessible, biologically grounded tools in the future.

Visit providers like ADHD Certify for personal consultations on emerging diagnostic approaches, including blood-based investigations.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Genetic studies and biomarkers.

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.